Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
543.14M | 528.29M | 399.36M | 329.23M | 305.51M | 260.89M | Gross Profit |
494.22M | 475.35M | 362.03M | 290.63M | 271.05M | 229.84M | EBIT |
38.60M | 24.88M | -73.49M | -204.43M | -199.92M | -243.85M | EBITDA |
53.63M | 29.39M | -92.08M | -199.58M | -202.87M | -242.98M | Net Income Common Stockholders |
-29.37M | -56.11M | -151.58M | -236.57M | -250.46M | -276.85M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
239.60M | 249.95M | 286.20M | 293.60M | 482.50M | 483.27M | Total Assets |
721.79M | 785.03M | 777.88M | 724.17M | 905.14M | 886.52M | Total Debt |
444.49M | 443.64M | 445.06M | 452.12M | 440.13M | 441.73M | Net Debt |
234.73M | 229.89M | 198.06M | 303.31M | 194.93M | 278.49M | Total Liabilities |
591.10M | 590.99M | 617.71M | 601.12M | 597.77M | 600.14M | Stockholders Equity |
130.69M | 194.04M | 160.17M | 123.05M | 307.37M | 286.38M |
Cash Flow | Free Cash Flow | ||||
1.61M | -37.44M | -76.53M | -170.34M | -206.38M | -236.52M | Operating Cash Flow |
3.56M | -33.89M | -69.09M | -166.57M | -202.49M | -233.29M | Investing Cash Flow |
-40.96M | -560.00K | 98.06M | 92.32M | 78.76M | -13.58M | Financing Cash Flow |
6.73M | 5.12M | 61.68M | -7.46M | 212.07M | 262.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $2.03B | ― | -18.12% | ― | 28.25% | 80.86% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
50 Neutral | $2.23B | ― | -103.82% | ― | 48.04% | 48.16% | |
50 Neutral | $2.99B | ― | -106.71% | ― | ― | -22.34% | |
46 Neutral | $2.94B | ― | -30.84% | ― | ― | -1.20% | |
45 Neutral | $2.55B | ― | -74.17% | ― | ― | -43.10% | |
43 Neutral | $3.53B | ― | -386.33% | ― | 33.46% | 26.72% |
On April 30, 2025, Amicus Therapeutics entered into a license agreement with Dimerix Bioscience, granting Amicus exclusive rights to develop, manufacture, and commercialize Dimerix’s drug candidate DMX-200 in the United States for Focal Segmental Glomerulosclerosis (FSGS) and other indications. This agreement, effective May 1, 2025, includes a $30 million upfront payment and potential milestone payments totaling up to $560 million. Dimerix will continue funding the ongoing pivotal Phase 3 study for DMX-200, while Amicus will handle regulatory submissions and commercialization in the U.S. This collaboration aims to bring a transformative treatment to patients with FSGS, a rare kidney disease with limited treatment options, enhancing Amicus’s portfolio in the rare disease market.